Of note, AT7519 likewise reduced phosphorylation of RNA polymerase II via CDK1/9 and affected expression levels of the oncoprotein N-Myc, making this compound a candidate for treatment of N-Myc-driven cancers. Here, CDK1 is linked to cancer.